Cardiff Oncology Inc
NASDAQ:CRDF
Cardiff Oncology Inc
Revenue
Cardiff Oncology Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cardiff Oncology Inc
NASDAQ:CRDF
|
Revenue
$488k
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
See Also
What is Cardiff Oncology Inc's Revenue?
Revenue
488k
USD
Based on the financial report for Dec 31, 2023, Cardiff Oncology Inc's Revenue amounts to 488k USD.
What is Cardiff Oncology Inc's Revenue growth rate?
Revenue CAGR 10Y
6%
Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for Cardiff Oncology Inc have been 10% over the past three years , 5% over the past five years , and 6% over the past ten years .